TD Asset Management Inc lifted its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 10.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 51,172 shares of the biotechnology company's stock after purchasing an additional 5,014 shares during the quarter. TD Asset Management Inc owned about 0.09% of Repligen worth $6,511,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of RGEN. KBC Group NV boosted its position in shares of Repligen by 14.9% during the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after buying an additional 329 shares during the period. LPL Financial LLC boosted its position in Repligen by 47.6% during the 4th quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock worth $4,873,000 after acquiring an additional 10,395 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Repligen by 40.1% during the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 274 shares in the last quarter. QRG Capital Management Inc. raised its holdings in shares of Repligen by 8.8% in the first quarter. QRG Capital Management Inc. now owns 2,548 shares of the biotechnology company's stock valued at $324,000 after purchasing an additional 206 shares during the last quarter. Finally, NBC Securities Inc. lifted its position in shares of Repligen by 133,600.0% in the first quarter. NBC Securities Inc. now owns 2,674 shares of the biotechnology company's stock worth $340,000 after purchasing an additional 2,672 shares in the last quarter. 97.64% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of research firms recently weighed in on RGEN. Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Stephens upgraded Repligen to an "overweight" rating and set a $160.00 price objective for the company in a report on Tuesday, July 22nd. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research report on Tuesday, April 29th. Royal Bank Of Canada upped their target price on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a report on Wednesday. Finally, Wells Fargo & Company decreased their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $169.45.
Read Our Latest Stock Analysis on RGEN
Repligen Stock Performance
RGEN opened at $118.91 on Friday. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The business has a 50 day moving average of $123.39 and a 200-day moving average of $136.49. The stock has a market cap of $6.68 billion, a price-to-earnings ratio of -475.62, a PEG ratio of 2.15 and a beta of 1.05.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.65%. The business had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same period in the prior year, the business earned $0.40 EPS. The company's revenue for the quarter was up 14.8% compared to the same quarter last year. On average, equities research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.
Repligen Company Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
